- Strong immune response after third yearly booster dose in children and adults
- Significant anamnestic antibody response across all six serotypes
- No safety concerns observed in any age group by independent Data Monitoring Committee (DMC), consistent with previous booster results.
Saint-Herblain (France), September 3rd, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease vaccine candidate, VLA15. The strong anamnestic immune response and favorable safety profile following a third booster dose were consistent with those reported after receiving previous annual booster doses[1],[2] further demonstrating compatibility with the anticipated benefits of a yearly vaccination prior to each Lyme season.
To access the full release, please click on the PDF below.